Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2021 | Novel treatment combinations for FLT3-mutated AML

Farhad Ravandi • 13 Dec 2021
ASH 2021
Acute Myeloid Leukemia Leukemia Decitabine Gilteritinib Midostaurin Quizartinib Venetoclax

Farhad Ravandi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares some of the most important updates in the treatment of FLT3-mutated acute myeloid leukemia (AML) presented at the ASH 2021 Annual Meeting. Dr Ravandi highlights studies evaluating combinations of FLT3 inhibitors such as gilteritinib, midostaurin and quizartinib with venetoclax and with chemotherapy, as well as triplet combination regimens with decitabine, venetoclax and quizartinib, and azacitidine, venetoclax and gilteritinib. He also comments on the development of menin inhibitors and their potential role in NPM1/FLT3-mutated AML. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Farhad Ravandi

Can persistent MRD negativity be considered therapy failure in AML? ELN definitions and relapse risk
2:04
Can persistent MRD negativity be considered therapy failure in AML? ELN definitions and relapse risk
Farhad Ravandi • 21 Sep 2026
Refining the role of MRD in AML: predicting relapse and the goal of MRD negativity
1:40
Refining the role of MRD in AML: predicting relapse and the goal of MRD negativity
Farhad Ravandi • 21 Sep 2026
Will MRD eradication become a routine treatment goal in AML?
1:09
Will MRD eradication become a routine treatment goal in AML?
Farhad Ravandi • 21 Sep 2026
Can current MRD assays accurately predict relapse in AML? Limitations and future directions
2:18
Can current MRD assays accurately predict relapse in AML? Limitations and future directions
Farhad Ravandi • 21 Sep 2026

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals